The incidence of interval cancers in the german mammography screening program: Results from the population-based cancer registry in North Rhine-Westphalia;Häufigkeit von Intervallkarzinomen im deutschen Mammographie- Screening-Programm: Auswertungen des Epidemiologischen Krebsregisters Nordrhein-Westfalen

Deutsches Arzteblatt International

Volumn 109, Issue 46, 2012, Pages 781-787

  Heidinger, Oliver ^a   Batzler, Wolf Ulrich ^a   Krieg, Volker ^a   Weigel, Stefanie ^b   Biesheuvel, Cornelis ^b   Heindel, Walter ^b   Hense, Hans Werner ^a,b  

^a Epidemiological Cancer Registry North Rhine Westphalia ^*  (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CLINICAL EFFECTIVENESS; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; INTERVAL CANCER; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MAMMOGRAPHY SCREENING PROGRAM; ONCOLOGICAL PARAMETERS; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; EARLY DIAGNOSIS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; RADIOGRAPHY; REGISTER; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GERMANY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84899780867     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0781     Document Type: Article

References (24)

1. Giersiepen K, Hense HW, Klug SJ, Antes G, Zeeb H: Planning, implementation and evaluation of cancer screening programs. Z Arztl Fortbild Qualitatssich 2007; 101: 43-9.
2. Raffle AE, Gray JAM: Screening: Evidence and practice. Oxford: Oxford University Press, 2007.
3. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, van Karsa L: European guidelines for quality assurance in breast cancer screen - ing and diagnosis. Fourth Edition. European Communities 2006.
4. Weigel S, Batzler WU, Decker T, Hense HW, Heindel W: First epidemiological analysis of breast cancer incidence and tumor characteristics after implementation of population-based digital mammography screnning. RoFo 2009; 18: 1144-50.
5. Biesheuvel C, Weigel S, Heindel W: Mammography Screening: Evidence, history and current practice in Germany and other European Countries. Breast Care 2011; 104-9.
6. Krieg V, Hense HW, Lehnert M, Mattauch V: Record Linkage mit kryptographierten Identitätsdaten in einem bevölkerungsbezogenen Krebsregister - Entwicklung, Umsetzung und Fehlerraten. Gesundheitswesen 2001; 63: 376-82.
7. Meyer M: Kontrollnummern und Record Linkage. In: Hentschel S, Katalinic A (eds.): Das Manual der epidemiologischen Krebsregistrierung. München, Wien, New York: W. Zuckerschwerdt Verlag 2008: 57-68.
8. Epidemiologisches Krebsregister Nordrhein-Westfalen gGmbH (ed.): Report 2011. www.krebsregister.nrw.de
9. Schmidtmann I, Hammer G, Sariyar M, Gerhold-Ay A: Abschlussbericht der Evaluation des Krebsregisters NRW Schwerpunkt Record Linkage. www.krebsregister.nrw.de/index.php?id=121
10. Kooperationsgemeinschaft Mammographie (ed.): Evaluationsbericht 2008-2009, Ergebnisse des Mammographie-Screening-Programms in Deutschland. Berlin 2012.
11. National Evaluation Team of Breast Cancer Screening (NETB) (ed.): National evaluation of breast cancer screenings in the Netherlands: 1990-2007 (XII); Twelth evaluation report. Rotterdam: Department of Public Health, Erasmus MC 2009.
12. Richtlinie des Gemeinsamen Bundesausschusses über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinie/ KFE-RL) in der Fassung vom 16. Dezember 2010 (in Kraft getreten am 3. März 2011); www.g-ba.de
13. Epidemiologisches Krebsregister Nordrhein-Westfalen gGmbH (ed.): Report 2010; www.krebsregister.nrw.de
14. Bulliard JL, Sasieni P, Klabunde C, De Landtsheer JP, Yankaskas BC, Fracheboud J: Methodological issues in international comparison of interval breast cancers. Int J Cancer 2006; 119: 1158-63.
15. Verfahren zur Bewertung der Wirksamkeit des Deutschen Mammographie-Screening-Programms auf die Senkung der Sterblichkeit durch Brustkrebs. Stellungnahme des Wissenschaftlichen Gremiums des Beirats der Kooperationsgemeinschaft Mammographie vom 17.10.2011. www.mammo-programm.de/ fachinformationen/aktuelle-publikationen-details.php?id=15
16. Törnberg S, Kemetli L, Ascunce N, Hofvind S, Anttila A, Seradour B, Paci E, Guldenfels C, Azavedo E, Frigerio A, Rodrigues V, Ponti A: A pooled analysis of interval cancer rates in six European countries. European Journal of Cancer Prevention 2010; 19: 87-93.
17. Giersiepen K, Haartje U, Hentschel S, Katalinic A, Kieschke J: Brustkrebsregistrierung in Deutschland: Tumorstadienverteilung in der Zielgruppe für das Mammographie-Screening. Dtsch Arztebl 2004; 101(30): 2117-21.
18. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A: Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries. Pathobiology 2009; 76: 90-7.
19. Stang A: Decline in hormone replacement prescription and fall in breast cancer incidence - an epidemiologic discussion. Dtsch Arztebl Int 2008; 105(16): 303-9.
20. Urbschat I, Kieschke J, Schlahnstedt-Jahn U, von Gehlen S, Thiel A, Jensch P: Beiträge bevölkerungsbezogener Krebsregister zur Evaluation des bundesweiten Mammographie-Screenings. Gesundheitswesen 2005; 67: 448-54.
21. Bennett RL, Sellars SJ, Moss SM: Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. Br J Cancer 2011; 104: 571-7.
22. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM: Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst 2008; 100: 1082-91.
23. Hofvind S, Skaane P: Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening. Fortschr Röntgenstr 2012; 184: 437-42.
24. Elmore JG, Fletcher SW: Overdiagnosis in breast cancer screening: time to tackle an underappreciated harm. Ann Intern Med 2012; 156: 536-7.